At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 410 enrolled
Drug / intervention
LY2452473 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction
In Brief
A Phase 2 clinical trial evaluating LY2452473, tadalafil, and 2 other interventions for Erectile Dysfunction. Completed, enrolled 410 participants across 36 sites.
Detailed Summary
The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartOct 2010
Primary CompletionNov 2011
TodayJul 2026
First PostedJul 12, 2010
Enrollment StartOct 1, 2010
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.0 years ago
Interventions
LY2452473drug
Administered orally, once daily for 12 weeks
tadalafildrug
Administered orally, once daily for 12 weeks
placebo (tadalafil)drug
Administered orally, once daily for 12 weeks
placebo (LY2452473)drug
Administered orally, once daily for 12 weeks